Lepton PharmaceuticalsLepton Pharmaceuticals
 
Lepton PharmaceuticalsLepton Pharmaceuticals
  • Home
  • About Us
    • About Us
    • Board of directors
    • Team
  • Our Products
    • Pipeline
    • LN-Cast-01
    • LN-008 si-MASP2
  • Our Science
    • miRNA based Castling
    • siRNA and miRNA
    • Non-coding RNA
    • siRNA Advantages
  • Contact Us
  • News

Latest News

bt_bb_section_bottom_section_coverage_image
  • News
26 July 2022
ERS Genomics and Lepton Pharmaceuticals LTD Enter CRISPR/Cas9 License Agreement
  • News
14 February 2022
Lepton signs Consulting Agreement with Cell Therapy Expert Dr. Elena Sotillo, Senior Research Scientist at the lab of Prof. Crystal Mackall founding director, Center for Cancer Cell Therapy, Stanford Cancer Institute, Palo Alto, Ca, USA 
  • News
04 February 2022
Prof. Malcolm K Brenner, M.D., Ph.D. Founding Director of Baylor College of Medicine’s Center for Cell and Gene Therapy Houston, TX US agreed to consult to Lepton
  • News
01 February 2022
Lepton signs Consulting Agreement with Dr. Paz Einat
  • News
02 December 2021
Lepton announces filing of a PCT application covering its proprietary breakthrough Castling Technology
  • News
14 June 2021
Lepton and the Medical Center University of Freiburg sign a Sponsored Research Agreement to use miRNA Castling Technology
  • News
10 February 2021
Axolabs gmbh and Lepton Pharmaceutical LTD, enter into master service agreement
https://www.leptonpharma.com/wp-content/uploads/2021/04/logo_white_big-160x160.png

© 2021 Lepton Pharmaceuticals Inc.  All rights reserved

Our products

  • LN-Cast-01
  • LN-008 siMASP2

Our science

  • Castling Technology
  • siRNA and miRNA
  • Non-coding RNA
  • siRNA Advantages

Terms of use

  • Terms of Use
  • Copyright Info
  • Privacy Policy